These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21435873)

  • 21. Dopamides, vanillylamides, ethanolamides, and arachidonic acid amides of anti-inflammatory and analgesic drug substances as TRPV1 ligands.
    Sinning C; Watzer B; De Petrocellis L; Di Marzo V; Imming P
    ChemMedChem; 2008 Dec; 3(12):1956-64. PubMed ID: 19003845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1.
    Westaway SM; Thompson M; Rami HK; Stemp G; Trouw LS; Mitchell DJ; Seal JT; Medhurst SJ; Lappin SC; Biggs J; Wright J; Arpino S; Jerman JC; Cryan JE; Holland V; Winborn KY; Coleman T; Stevens AJ; Davis JB; Gunthorpe MJ
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5609-13. PubMed ID: 18809327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
    Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
    J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
    Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM
    Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists.
    Gore VK; Ma VV; Tamir R; Gavva NR; Treanor JJ; Norman MH
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5825-30. PubMed ID: 17851073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility.
    Wang X; Chakrabarti PP; Ognyanov VI; Pettus LH; Tamir R; Tan H; Tang P; Treanor JJ; Gavva NR; Norman MH
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6539-45. PubMed ID: 17937985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterocycle-linked phenylbenzyl amides as novel TRPV1 antagonists and their TRPV1 binding modes: constraint-induced enhancement of in vitro and in vivo activities.
    Kim NJ; Li FN; Lee JH; Park SG; Kim K; Lim C; Han YT; Yun H; Jung JW; Park HG; Kim HD; Woo BY; Shin SS; Kim SY; Choi JK; Jeong YS; Park Y; Park YH; Kim DD; Choi S; Suh YG
    Chem Asian J; 2013 Feb; 8(2):400-9. PubMed ID: 23208797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.
    Gomtsyan A; Bayburt EK; Keddy R; Turner SC; Jinkerson TK; Didomenico S; Perner RJ; Koenig JR; Drizin I; McDonald HA; Surowy CS; Honore P; Mikusa J; Marsh KC; Wetter JM; Faltynek CR; Lee CH
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3894-9. PubMed ID: 17507218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists.
    Stec MM; Bo Y; Chakrabarti PP; Liao L; Ncube M; Tamayo N; Tamir R; Gavva NR; Treanor JJ; Norman MH
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5118-22. PubMed ID: 18722118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological evaluation of 5-substituted and 4,5-disubstituted-2-arylamino oxazole TRPV1 antagonists.
    Perner RJ; Koenig JR; Didomenico S; Gomtsyan A; Schmidt RG; Lee CH; Hsu MC; McDonald HA; Gauvin DM; Joshi S; Turner TM; Reilly RM; Kym PR; Kort ME
    Bioorg Med Chem; 2010 Jul; 18(13):4821-9. PubMed ID: 20570528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
    Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
    J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
    Gomtsyan A; Bayburt EK; Schmidt RG; Surowy CS; Honore P; Marsh KC; Hannick SM; McDonald HA; Wetter JM; Sullivan JP; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2008 Feb; 51(3):392-5. PubMed ID: 18183945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spiro-piperidine azetidinones as potent TRPV1 antagonists.
    Xiao D; Palani A; Aslanian R; McKittrick BA; McPhail AT; Correll CC; Phelps PT; Anthes JC; Rindgen D
    Bioorg Med Chem Lett; 2009 Feb; 19(3):783-7. PubMed ID: 19114307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of indole-based peptoids as potent noncompetitive antagonists of transient receptor potential vanilloid 1.
    Quintanar-Audelo M; Fernández-Carvajal A; Van Den Nest W; Carreño C; Ferrer-Montiel A; Albericio F
    J Med Chem; 2007 Nov; 50(24):6133-43. PubMed ID: 17985859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and biological evaluation of novel biphenyl-4-carboxamide derivatives as orally available TRPV1 antagonists.
    Oka H; Yonezawa K; Kamikawa A; Ikegai K; Asai N; Shirakami S; Miyamoto S; Watanabe T; Kiso T; Takemoto Y; Tamura S; Kuramochi T
    Bioorg Med Chem; 2018 Jul; 26(12):3716-3726. PubMed ID: 29887511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of phenylpropanamides as novel transient receptor potential vanilloid 1 antagonists.
    Li FN; Kim NJ; Nam YH; Kim SH; Seo SY; Jeong YS; Kim SY; Park YH; Suh YG
    Arch Pharm Res; 2009 Sep; 32(9):1201-10. PubMed ID: 19784574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenyl isoxazole voltage-gated sodium channel blockers: structure and activity relationship.
    Macsari I; Sandberg L; Besidski Y; Gravenfors Y; Ginman T; Bylund J; Bueters T; Eriksson AB; Lund PE; Venyike E; Arvidsson PI
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3871-6. PubMed ID: 21641215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of TRPV1 antagonist ABT-116.
    Brown BS; Keddy R; Perner RJ; DiDomenico S; Koenig JR; Jinkerson TK; Hannick SM; McDonald HA; Bianchi BR; Honore P; Puttfarcken PS; Moreland RB; Marsh KC; Faltynek CR; Lee CH
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3291-4. PubMed ID: 20457518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of Analogues of BCTC Incorporating a Pyrrolidinyl Linker and Biological Evaluation as Transient Receptor Potential Vanilloid 1 Antagonists.
    Yan L; Wang J; Pan M; Qiu Q; Huang W; Qian H
    Chem Biol Drug Des; 2016 Feb; 87(2):306-11. PubMed ID: 26360809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinically useful vanilloid receptor TRPV1 antagonists: just around the corner (or too early to tell)?
    Appendino G; Szallasi A
    Prog Med Chem; 2006; 44():145-80. PubMed ID: 16697897
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.